How is masteron dosed per week, and how many mL is that?

200 mg of Drostanolone Enanthate (Masteron Enanthate) at 200 mg/mL is 1 mL, the 100 mark on a U-100 syringe.

Every vial at a glance. Pick a cell to draw it on the syringe.

Each row is a concentration; units are the dose over the concentration, times 100, on a U-100 syringe.
ConcentrationDraw per dose
200 mg/mL200 mg/mL: 50 mg is 0.25 mL, the 25 mark, 100 mg is 0.5 mL, the 50 mark, 200 mg is 1 mL, the 100 mark, 250 mg is over 1 mL

Most often logged by Milligram users: 200 mg, 17% logged.10

A DailyMed search found no US label for drostanolone; of people logging masteron enanthate in Milligram, 17% set up 200 mg a dose and 13% set up 100 mg, and the median weekly total set up is 338 mg, with a lower quartile of 189 mg and an upper quartile of 500 mg.110

mL and syringe units per dose at 200 mg/mL

Of the people logging masteron enanthate in Milligram, 72% set up 200 mg/mL.10 Of the people logging masteron enanthate, 13% set up 200 mg at 100 units, 11% 50 mg at 25 units and 10% 100 mg at 50 units.10 Of the people logging masteron enanthate, 7% set up 250 mg, which at 200 mg/mL is 1.25 mL, more than a 1 mL syringe holds.10

200 mg of Drostanolone Enanthate (Masteron Enanthate) at 200 mg/mL is 1 mL, the 100 mark on a U-100 syringe.

200 mg of Drostanolone Enanthate (Masteron Enanthate) at 200 mg/mL is 1 mL, the 100 mark on a U-100 syringe. Set to 200 mg, the dose most often logged by Milligram users (17%).10

What label and trial searches found

DailyMed searches for drostanolone and for the brand name masteron both returned no label records.12 A ClinicalTrials.gov search for drostanolone returned zero registered studies.3 The published summaries of the trials in the table name drostanolone or drostanolone propionate in breast cancer; none names the enanthate or states a dose or route, and their full texts were not obtained.

TrialDose and schedulePeopleLength
Clavel et al., 19824Tamoxifen plus drostanolone propionate (34 women), against CMF chemotherapy (30) or both combined (34); no dose stated98 post-menopausal women with breast cancerNot given
Wolff and Rieche, 19785Drostanolone against testololactone and nandrolone, with cyclophosphamide added in the second interval; no dose stated; remission rate averaged 24% at 4 weeks and 46% at 16 weeks, with no difference between the three drugs91 patients with advanced breast cancerRemissions checked after 4 weeks and after another 12 week period
Rieche and Wolff, 19756Drostanolone plus cyclophosphamide, against testosterone decanoate or testolactone each plus cyclophosphamide, which did better; no dose statedDisseminated breast cancer; number not givenObservation period of 10 to 16 weeks
Bennett et al., 19757Drostanolone propionate (Masteril) against oophorectomy (premenopausal), nandrolone phenylpropionate (perimenopausal) and ethinyl oestradiol (postmenopausal); no dose statedBreast cancer patients in three menopausal groups; number not givenTrial run from 1968 to 1972

What Milligram users log

Of the people who logged masteron enanthate doses, 17% set up 200 mg, 13% 100 mg, 9% 50 mg and 7% 250 mg.10 Of the same people, the median logged was 3.0 doses a week, and 7% set up 250 mg.10

Of the people who logged masteron enanthate, 67% also logged testosterone enanthate, and 12% of people logging testosterone enanthate also logged Masteron enanthate.10

Storage

With no label returned by the DailyMed search and no stability data in any saved source, the sources searched give no storage temperature, container or time for masteron enanthate.1

Frequently asked questions

Which route do people log for masteron enanthate?

Of the people who logged masteron enanthate, 95% logged the muscle route.10 A DailyMed search found no US label to give a route, and the published summaries of the trials in the table do not state one.1

Is a vial listed at 200 mg/mL always 200 mg/mL?

In a 2025 Queensland drug-checking study by Piatkowski and colleagues, which tested 58 anabolic steroid samples submitted in 2024, samples sold as drostanolone enanthate (Masteron) were listed at 200 mg/mL.8 Two of these samples measured 201 and 203 mg/mL and were judged to match their label, and two measured 215 and 257 mg/mL and were judged overdosed.8 Of the study's 46 analysable samples of all kinds, 15 had purity issues, meaning the concentration was either too low or too high.8

Was drostanolone ever used as a medicine?

A 2021 review of testosterone and related steroids by Tauchen and colleagues says drostanolone has been removed from medicinal use, although it was of value in certain types of breast cancer.9

How the logged figures are counted

Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

References

  1. US National Library of Medicine, DailyMed. DailyMed label search for drostanolone (US National Library of Medicine), searched 2026-11-17. 2026. dailymed.nlm.nih.gov
  2. US National Library of Medicine, DailyMed. DailyMed label search for masteron (US National Library of Medicine), searched 2026-11-17. 2026. dailymed.nlm.nih.gov
  3. US National Library of Medicine, ClinicalTrials.gov. ClinicalTrials.gov registry search for drostanolone, searched 2026-11-17. 2026. clinicaltrials.gov
  4. La Semaine des Hopitaux (PubMed abstract). Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both. 1982. pubmed.ncbi.nlm.nih.gov
  5. Onkologie (PubMed abstract). Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone. 1978. pubmed.ncbi.nlm.nih.gov
  6. Archiv fur Geschwulstforschung (PubMed abstract). Comparison of testosterone decanoate, drostanolone and testololactone in disseminated breast cancer--a randomized clinical study. 1975. pubmed.ncbi.nlm.nih.gov
  7. South African Medical Journal (PubMed abstract). Hormonal therapy of breast cancer with special reference to Masteril therapy. 1975. pubmed.ncbi.nlm.nih.gov
  8. Piatkowski T et al., Harm Reduction Journal / PMC. Anabolic-androgenic steroid testing as a tool for consumer engagement and harm reduction: a sequential explanatory mixed-method study. 2025. pmc.ncbi.nlm.nih.gov
  9. Tauchen J et al., Molecules. Medicinal Use of Testosterone and Related Steroids Revisited. 2021. pmc.ncbi.nlm.nih.gov
  10. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted